Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population
- PMID: 31675127
- DOI: 10.1002/ana.25634
Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population
Comment in
-
Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population".Ann Neurol. 2020 Jan;87(1):155. doi: 10.1002/ana.25633. Epub 2019 Nov 14. Ann Neurol. 2020. PMID: 31675120 No abstract available.
Comment on
-
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.Ann Neurol. 2018 Nov;84(5):648-658. doi: 10.1002/ana.25334. Epub 2018 Oct 4. Ann Neurol. 2018. PMID: 30196548 Free PMC article.
References
-
- Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018;84:648-658.
-
- Jack CR Jr, Bennet DA, Blennow K, et al. NIAA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer Dement 2018;14:535-562.
-
- Picard RR, Cook D. Cross-validation of regression models. J Am Stat Assoc 1984;79:387,575-583.
-
- Zwan MD, Villemagne VL, Doré V, et al. Subjective memory complaints in APOE ε4 carriers are associated with high amyloid-β burden. J Alzheimers Dis 2016;49:1115-1122.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
